DelveInsight’s “Developmental and Epileptic Encephalopathy Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of DEE, historical and forecasted epidemiology as well as DEE market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

Unlock key insights into the Developmental and Epileptic Encephalopathies Market! Download DelveInsight’s comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Developmental and Epileptic Encephalopathies Market Size

 

Key Takeaways from the Developmental and Epileptic Encephalopathies Market Report

• In December 2024:- Longboard Pharmaceuticals- The objective of this study is to assess the long-term safety, tolerability, and efficacy of adjunctive therapy of LP352 in subjects with developmental and epileptic encephalopathies who completed participation in Study LP352-201.
• The total number of diagnosed prevalent cases of DEE in the 7MM was nearly 284,000 cases in 2023 and are projected to increase during the forecasted period.
• Lennox-Gastaut syndrome (LGS) and Tuberous sclerosis complex (TSC) asscociated epilepsy are the largest contributors to the overall DEE pool. The prevalent cases of DEE in the United States were nearly 50,000 for LGS and nearly 47,100 for TSC with epilepsy in 2023.
• The total number of cases in EU4 and the UK for DEE was estimated to be nearly 104,000 cases in 2023.
• Among EU4 and the UK, the highest number of cases for DEE was found in Germany which was estimated to nearly 34% of cases in EU4 and the UK in 2023.
• The total number of cases in Japan for DEE was estimated to be nearly 34,000 cases in 2023.
• The leading Developmental and Epileptic Encephalopathies Companies such as Jazz Pharmaceuticals, Biocodex, Zogenix (Acquired by UCB), Lundbeck, Marinus Pharmaceuticals, Novartis, Aquestive Therapeutics, Supernus Pharmaceuticals, Lundbeck, Eisai Pharmaceuticals, GlaxoSmithKline, Meda Pharmaceuticals, Roche, Questcor Pharmaceuticals/Mallinckrodt Pharmaceuticals, Xenon Pharmaceuticals, Takeda/Ovid Therapeutics, SK Life Science, Epygenix, Neurocrine Biosciences, Stoke Therapeutics, Neurocrine Biosciences, BioPharm Solutions, Praxis Precision Medicines, Epygenix, Longboard Pharmaceuticals, and others.
• Promising Developmental and Epileptic Encephalopathies Therapies such as LP352, Bexicaserin, Soticlestat, and others.

 

Stay ahead in the competitive landscape of the Developmental and Epileptic Encephalopathies Market. Access DelveInsight’s in-depth market analysis and strategic insights today! Click here for more @ Developmental and Epileptic Encephalopathies Treatment Market Size

 

Developmental and Epileptic Encephalopathies Epidemiology Segmentation in the 7MM

• Total Developmental and Epileptic Encephalopathies Diagnosed Prevalent Cases
• Developmental and Epileptic Encephalopathies Cases by Subtypes

 

Download the report to understand which factors are driving Developmental and Epileptic Encephalopathies epidemiology trends @ Developmental and Epileptic Encephalopathies Prevalence

 

Developmental and Epileptic Encephalopathies Marketed Drugs

• EPIDIOLEX (cannabidiol): Jazz Pharmaceuticals

EPIDIOLEX, also known as EPIDYOLEX in Europe, is the first prescription, plant-derived cannabis oral formulation developed by GW Pharmaceuticals. It is a novel class of antiepileptic medications with a different mechanism of action. The drug is the first FDA-approved drug that contains a purified drug substance derived from marijuana, and the active ingredient is cannabidiol (CBD). Under the Controlled Substances Act (CSA), CBD is classified as a Schedule I substance; thus, GW Pharmaceuticals conducted nonclinical and clinical studies to assess the abuse potential of CBD to support its usage.

 

• FINTEPLA (fenfluramine): UCB

FINTEPLA (formerly known as ZX008) is an oral medication that is a low-dose solution of fenfluramine hydrochloride. It prevents the entry of calcium ions into nerve cells, lowering their over-excitability and reducing seizure episodes. It also activates serotonin receptors, which contribute to the overall antiepileptic action.

 

Developmental and Epileptic Encephalopathies Emerging Drugs

• Zorevunersen (STK-001): Stoke Therapeutics

Zorevunersen is an investigational new medicine for the treatment of Dravet syndrome. It is a proprietary antisense oligonucleotide (ASO) and has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome. The drug is designed to upregulate NaV1.1 protein expression by leveraging the non-mutant copy of the SCN1A gene to restore physiological NaV1.1 levels, thereby reducing both occurrences of seizures and significant non-seizure comorbidities.

 

• Bexicaserin (LP352): Longboard Pharmaceuticals

Bexicaserin is an oral, centrally acting, 5-HT2c superagonist in development for the potential treatment of seizures associated with DEEs such as Dravet syndrome, LGS, tuberous sclerosis complex (TSC), CDKL5 deficiency disorder (CDD), and other epileptic disorders. LP352 is designed to modulate GABA and, as a result, suppress the central hyperexcitability that is characteristic of seizures. LP352 is the only 5-HT2c receptor superagonist being dose-optimized for the refractory epilepsy population.

 

Discover the future of Developmental and Epileptic Encephalopathies treatments with DelveInsight’s latest market report. Get expert insights and forecasts—download now! @ Developmental and Epileptic Encephalopathies Market Drivers and Barriers

 

Developmental and Epileptic Encephalopathies Market Outlook

In recent years, three antiseizure medications have been approved as adjunct therapy in patients with Dravet Syndrome: DIACOMIT (Stiripentol), which was approved in the US in 2018 and received full European marketing authorization in 2014, EPIDIOLEX (cannabidiol) which was approved by the FDA in 2018, and FINTEPLA (fenfluramine), which was approved in 2020 in the US and EU. These treatments are “add-on” therapies (most usually used in conjunction with Valproate and clobazam) with availability and recommendations in various countries influencing the decision in the EU.

 

Developmental and Epileptic Encephalopathies Drugs Market

Disease-modifying therapies represent a significant leap forward in the treatment of Developmental and Epileptic Encephalopathies (DEE). These innovative approaches have the potential to transform the landscape of care, offering new hope to patients and families affected by these challenging conditions. For instance, if approved, STK-001 could become the first disease-modifying medicine for Dravet syndrome, a severe form of epilepsy. This breakthrough would not only address the symptoms but also target the underlying causes of the disease, marking the dawn of a new era in DEE treatment.

 

Explore the dynamics of the Developmental and Epileptic Encephalopathies Market with DelveInsight. From market size to emerging drugs—find it all in our latest report. Read now! @ Developmental and Epileptic Encephalopathies Ongoing Clinical Trials Analysis

 

Scope of the Developmental and Epileptic Encephalopathies Market Report

• Coverage- 7MM
• Study Period- 2020-2034
• Developmental and Epileptic Encephalopathies Companies- Jazz Pharmaceuticals, Biocodex, Zogenix (Acquired by UCB), Lundbeck, Marinus Pharmaceuticals, Novartis, Aquestive Therapeutics, Supernus Pharmaceuticals, Lundbeck, Eisai Pharmaceuticals, GlaxoSmithKline, Meda Pharmaceuticals, Roche, Questcor Pharmaceuticals/Mallinckrodt Pharmaceuticals, Xenon Pharmaceuticals, Takeda/Ovid Therapeutics, SK Life Science, Epygenix, Neurocrine Biosciences, Stoke Therapeutics, Neurocrine Biosciences, BioPharm Solutions, Praxis Precision Medicines, Epygenix, Longboard Pharmaceuticals, and others.
• Developmental and Epileptic Encephalopathies Therapies- LP352, Bexicaserin, Soticlestat, and others.
• Developmental and Epileptic Encephalopathies Therapeutic Assessment: Developmental and Epileptic Encephalopathies Current Marketed and Developmental and Epileptic Encephalopathies Emerging Therapies
• Developmental and Epileptic Encephalopathies Market Dynamics: Developmental and Epileptic Encephalopathies market drivers and Developmental and Epileptic Encephalopathies market barriers
• Developmental and Epileptic Encephalopathies Unmet Needs, KOL’s views, Analyst’s views, Developmental and Epileptic Encephalopathies Market Access and Reimbursement

 

Table of Content

1. Key Insights

2. Report Introduction

3. Executive Summary

4. DEE Market Overview at a Glance

5. Key Events

6. Epidemiology and Market Methodology

7. Disease Background and Overview

8. Treatment of DEE

9. Epidemiology and Patient Population

10. Patient Journey

11. Marketed Drugs

12. Emerging Drugs

13. DEE: The 7MM Analysis

14. Unmet Needs

15. SWOT Analysis

16. KOL Views

17. Market Access and Reimbursement

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/catheter-stabilization-securement-device-market